Company Overview and News

1
Converge ICT to partner with KT for 3rd telco bid

2018-10-15 bworldonline
THE Department of Information and Communications Technology (DICT) said Converge ICT Solutions, Inc. has committed to joining the government’s bid for a new telecommunications player, with South Korean telecommunications giant KT Corp. as its partner.
K3ED CHJHF NOW KT CHA 0728 DNOW

1
China Telecom buys bid documents for ‘third player’ selection

2018-10-12 bworldonline
CHINA Telecom Corp. Ltd. became the second foreign company to buy bid documents to become the telecommunications industry’s third entrant — the so-called “third player” — with the selection process also getting a boost after a Manila court denied a petition for a temporary restraining order (TRO) by a participant questioning the bid terms.
K3ED CHJHF NOW CHA 0728 DNOW

2
Muted foreign interest in 3rd telco slot

2018-10-08 bworldonline - 1
FOUR LOCAL FIRMS and only one foreign company, Norway’s Telenor Group, firmed up their interest in participating in the auction for the country’s third major telecommunications service provider by purchasing the bid documents on Monday — the first day of its availability.
K3ED CHJHF NOW GTMEY CHA ECP GLOPP GLO KT 0728 GTMEF GLOPA DNOW

3
‘Serious’ query from Vodafone about 3rd player auction — Diokno

2018-10-03 bworldonline - 1
THE UK’s Vodafone Group PLC has discussed with the government the possibility of participating in the selection process for the telecommunications industry’s so-called “third player,” Budget Secretary Benjamin E. Diokno said following a visit to London.
K3ED VOD CHJHF VOD VODPF NOW KT CHA 0728 ECP DNOW

1
Final timetable for 3rd major telco set

2018-10-02 bworldonline
THE DEPARTMENT of Information and Communications Technology (DICT) presented on Tuesday the final timetable for selection of the country’s third major telecommunications service provider, with documents available for purchase by interested parties starting Oct. 8, Monday.
K3ED CHJHF NOW GTMEY CHA ECP GLOPP GLO KT 0728 GTMEF GLOPA DNOW

1
Telenor in talks with potential partners to enter PHL market

2018-09-30 bworldonline
NORWAY’S Telenor Group said it is in talks with local companies as it eyes participation in the bidding for the third player slot in the Philippine telco industry.
K3ED CHJHF NOW GTMEY CHA ECP GLOPP GLO KT 0728 GTMEF GLOPA DNOW

 
To boost 5G, keep the industry free

2018-09-29 thestar.com.my
EUROPE and Asia are poised to surge past the US when it comes to mobile Internet innovation. At a White House summit yesterday on next-generation mobile broadband, or “5G,” industry luminaries and government leaders gathered to discuss how America can retain its dominance in this vital economic arena.
K3ED CHJHF CHA 0728

10
China Tower opens with a whimper in Hong Kong debut as investors tire of stock offerings

2018-09-26 scmp
China Tower, the US$6.9 billion stock sale that has been hogging headlines as the world’s largest initial public offering (IPO) of 2018, opened with a whimper in Hong Kong, extending the trend of lacklustre debuts as investors appear to have grown tired of blockbuster stock sales.
0941 K3ED BABA 0762 CHLKF CHL CHJHF CHUFF CHA 0728 CHU

1
Selection of third major telco on track by December as gov’t issues final terms

2018-09-21 bworldonline
THE DEPARTMENT of Information and Communications Technology (DICT) and the National Telecommunications Commission (NTC) published on Friday the final terms of reference (ToR) outlining the process by which the government will select by December a third major player in the telecommunications industry.
K3ED CHJHF NOW GTMEY CHA ECP GLOPP GLO KT 0728 GTMEF GLOPA DNOW

14
Interactive Brokers - U.S. Telecom Stocks Surge As 5G Ambitions Intensify

2018-09-20 seekingalpha
U.S.-based telecom sector stocks have been soaring amid progress towards advancing 5G (next generation) technology and despite global competition.
XLNX K3ED CHLKF CHJHF TMUS CMCSA CHA 0941 0762 CHL CHUFF ADI VZ 0728 CCI CHU QCOM

 
China Mobile: Critical Infrastructure Asset Near 52-Week Lows

2018-09-13 seekingalpha
Over the past decade, the company has achieved average return on equity (ROE) and return on invested capital (ROIC) of 17.2% and 15.5%, respectively.
0941 K3ED 0762 CHLKF CHL CHJHF CHUFF CHA 0728 CHU

 
Asia Markets: Asian stocks a bit of a mess, with widespread declines

2018-09-05 marketwatch
Asian stock markets posted broad declines in early trading Wednesday, after Wall Street finished weakly following a holiday weekend and European markets fell further after a pause on Monday.
K3ED CHJHF CHA 0728

 
Why a Massive China Telecom Merger Matters to the US

2018-09-04 247wallst
Two of China’s three largest wireless carriers are reportedly discussing a merger. China Unicom (Hong Kong) Ltd. (NYSE: CHU) and China Telecommunications Corp. Ltd. (NYSE: CHA) are both state-controlled wireless carriers and the second- and third-largest wireless carriers in the country with a combined total of more than 590 million subscribers. China Mobile Ltd. (NYSE: CHL), the country’s largest wireless carrier with more than 900 million subscribers, is also a state-controlled enterprise.
0941 K3ED 0762 CHLKF CHL CHJHF CHUFF CHA 0728 CHU

15
Deals of the day-Mergers and acquisitions

2018-09-04 reuters - 1
Sept 4 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1200 GMT on Tuesday:
K3ED BGX SNMYF CHJHF CHA SMGKF SNMCY BX BGLF ORIG BGB SMIN 0762 SMGZY CHUFF SUN 0728 ICUI IOF 8750 CHU RIG SGAZF

5
China is said to explore megamerger of mobile-phone carriers

2018-09-04 theedgemarkets
BEIJING (Sept 4): China is exploring a merger between two of the nation’s three wireless carriers to speed up the development of 5G mobile services amid a race with the US over the technology, according to people familiar with the matter.
K3ED CHLKF CHJHF CHA 0941 0762 CHL CHUFF AVGO 0728 BRCM CHU QCOM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...